Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease

Neurotoxicity Research

Volumn 16, Issue 3, 2009, Pages 261-270

  Federoff, Howard J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

NuIP; Nurr1; Parkinson's disease; VIP

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; NUCLEAR RECEPTOR RELATED FACTOR 1; NUCLEAR RECEPTOR RELATED FACTOR 1 INTERACTING PROTEIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; DOPAMINERGIC NERVE CELL; LIGAND BINDING; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; DOPAMINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; MODELS, BIOLOGICAL; NERVE GROWTH FACTORS; NEURONS; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; PARKINSON DISEASE; RNA, SMALL NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

MAMMALIA;

EID: 70349913868     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9056-7     Document Type: Article

References (66)

1. Alam M, Schmidt WJ (2002) Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 136:317-324
2. Bäckman C, Perlmann T, Wallén A, Hoffer B, Morales M (1999) A selective group of dopaminergic neurons express NURR1 in the adult mouse brain. Brain Res 851:125-132
3. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306
4. Blondel O, Collin C, McCarran WJ, Zhu S, Zamostiano R, Gozes I, Brenneman DE, McKay RD (2000) A glia-derived signal regulating neuronal differentiation. J Neurosci 20:8012-8020
5. Brooks AI, Chadwick CA, Gelbard HA, Cory-Slechta DA, Federoff HJ (1999) Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823:1-10
6. Carmine A, Buervenich S, Galter D, Jonsson EG, Sedvall GC, Farde L, Gustavsson JP, Bergman H, Chowdari KV, Nimgaonkar VL, Anvret M, Sydow O, Olson L (2003) NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits. Am J Med Genet B Neuropsychiatr Genet 120:51-57
7. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991-998
8. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A (2000) Inflammatory changes in the substantia nigra and striatum following MPTP intoxication. Ann Neurol 48:127
9. Czlonkowska A, Kurkowska-Jastrzebska I, Czlonkowski A, Peter D, Stefano GB (2002) Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit 8:RA165-RA177
10. Delgado M, Ganea D (2003a) Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: Potential therapeutic role in brain trauma. Faseb J 17:1922-1924
11. Delgado M, Ganea D (2003b) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. Faseb J 17:944-946
12. Delgado M, Jonakait GM, Ganea D (2002) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39:148-161
13. Delgado M, Pozo D, Ganea D (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56:249-290
14. Delgado M, Varela N, Gonzalez-Rey E (2008) Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia 56:1091-1103
15. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson's disease. J Neurochem 81:1285-1297
16. Gao HM, Liu B, Zhang W, Hong JS (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24:395-401
17. Gozes I, Brenneman DE (1996) Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci 7:235-244
18. Gressens P (1999) VIP neuroprotection against excitotoxic lesions of the developing mouse brain. Ann N Y Acad Sci 897:109-124
19. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P (1997) Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Investig 100:390-397
20. Hartmann A, Hunot S, Hirsch EC (2003) Inflammation and dopaminergic neuronal loss in Parkinson's disease: A complex matter. Exp Neurol 184:561-564
21. Heikkila RE, Sonsalla PK (1992) The MPTP-treated mouse as a model of parkinsonism: How good is it? Neurochem Int 20(Suppl):299S-303S
22. Hering R, Petrovic S, Mietz EM, Holzmann C, Berg D, Bauer P, Woitalla D, Muller T, Berger K, Kruger R, Riess O (2004) Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology 62:1231-1232
23. Hermanson E, Joseph B, Castro D, Lindqvist E, Aarnisalo P, Wallen A, Benoit G, Hengerer B, Olson L, Perlmann T (2003) Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 288:324-334
24. Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in Parkinson's disease: A role in neurodegeneration? Ann Neurol 44:S115-S120
25. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 991:214-228
26. Iversen L, Foster AC, Hill RG, Iversen SD, Kemp JA, Leeson PD, Rupniak NM, Saywell K, Tricklebank MD, Williams BJ (1992) Neurotoxin-related research: From the laboratory to the clinic. Ann N Y Acad Sci 648:207-218
27. Iwayama-Shigeno Y, Yamada K, Toyota T, Shimizu H, Hattori E, Yoshitsugu K, Fujisawa T, Yoshida Y, Kobayashi T, Toru M, Kurumaji A, Detera-Wadleigh S, Yoshikawa T (2003) Distribution of haplotypes derived from three common variants of the NR4A2 gene in Japanese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 118:20-24
28. Jakowec MW, Petzinger GM (2004) 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp Med 54:497-513
29. Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476:388-413
30. Kim K-S, Kim C-H, Hwang D-Y, Seo H, Chung S, Hong SJ, Lim J-K, Anderson T, Isacson O (2003) Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem 85:622-634
31. Langston JW, Ballard PA Jr (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med 309:310
32. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
33. Law SW, Conneely OM, DeMayo FJ, O'Malley BW (1992) Identification of a new brain-specific transcription factor, Nurr1. Mol Endocrinol 6:2129-2135
34. W-d Le, Conneely OM, He Y, Jankovic J, Appel SH (1999a) Reduced nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 73:2218-2221
35. W-d Le, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, Jankovic J, Mosier DR, Appel SH (1999b) Selective agenesis of mesencephalic dopaminergic neurons in Nurr1 - deficient mice. Exp Neurol 159:451-458
36. Le W, Chen S, Jankovic J (2009) Etiopathogenesis of Parkinson disease: A new beginning? Neuroscientist 15:28-35
37. Levecque C, Destee A, Mouroux V, Amouyel P, Chartier-Harlin MC (2004) Assessment of Nurr1 nucleotide variations in familial Parkinson's disease. Neurosci Lett 366:135-138
38. Luo Y, Henricksen LA, Giuliano RE, Prifti L, Callahan LM, Federoff HJ (2007) VIP is a transcriptional target of Nurr1 in dopaminergic cells. Exp Neurol 203:221-232
39. Luo Y, Xing F, Guiliano R, Federoff HJ (2008) Identification of a novel nurr1-interacting protein. J Neurosci 28:9277-9286
40. Maguire-Zeiss KA, Federoff HJ (2003) Convergent pathobiologic model of Parkinson's disease. Ann N Y Acad Sci 991:152-166
41. McCormack AL, Di Monte DA (2003) Effects of l-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem 85:82-86
42. McGeer PL, McGeer EG (1998) Glial cell reactions in neurodegenerative diseases: Pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 12(Suppl 2):S1-S6
43. McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson's disease. Adv Neurol 86:83-89
44. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T (2004) Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord 19:649-655
45. Orth M, Tabrizi SJ (2003) Models of Parkinson's disease. Mov Disord 18:729-737
46. Perier C, Bove J, Vila M, Przedborski S (2003) The rotenone model of Parkinson's disease. Trends Neurosci 26:345-346
47. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991:189-198
48. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, Gasser T, Stoltze L (2007) Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 188:117-127
49. Sacchetti P, Mitchell TR, Grannerman JG, Bannon MJ (2001) Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 76:1565-1572
50. Sakurada K, Ohshma-Sakurada M, Palmer T, Gage F (1999) NURR1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development 126:4017-4026
51. Saucedo-Cardenas O, Kardon R, Ediger TR, Lydon JP, Conneely OM (1997) Cloning and structural organization of the gene encoding the murine nuclear receptor transcription factor, NURR1. Gene 187:135-139
52. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, Smidt MP, Cox JJ, De Mayo F, Burbach JP, Conneely OM (1998) Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 95:4013-4018
53. Smits SM, Ponnio T, Conneely OM, Burbach JPH, Smidt MP (2003) Involvement of Nurr1 in specifying the neurotransmitter identity of ventral midbrain dopaminergic neurons. Eur J NeuroSci 18:1731-1738
54. Steingart RA, Solomon B, Brenneman DE, Fridkin M, Gozes I (2000) VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress. J Mol Neurosci 15:137-145
55. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2007) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29(11):1690-1701
56. Tan EK, Chung H, Zhao Y, Shen H, Chandran VR, Tan C, Teoh ML, Yih Y, Pavanni R, Wong MC (2003) Genetic analysis of Nurr1 haplotypes in Parkinson's disease. Neurosci Lett 347:139-142
57. Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, Langston JW (1999) Parkinson disease in twins: An etiologic study. JAMA 281:341-346
58. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA (2000) The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for Parkinson's disease. J Neurosci 20:9207-9214
59. Trojanowski JQ (2003) Rotenone neurotoxicity: A new window on environmental causes of Parkinson's disease and related brain amyloidoses. Exp Neurol 179:6-8
60. Wang Z, Benoit G, Liu J, Prasad S, Aarnisalo P, Liu X, Xu H, Walker NP, Perlmann T (2003) Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 423:555-560
61. Wersinger C, Sidhu A (2002) Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 1:221-242
62. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R (2003) Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: Implications for Parkinson's disease. Faseb J 17:500-502
63. Wullner U, Klockgether T (2003) Inflammation in Parkinson's disease. J Neurol 250(Suppl 1):I35-I38
64. Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, Lai D, Le WD (2002) Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 58:881-884
65. Zetterström R, Solomin L, Jansson L, Hoffer B, Olson L, Perlmann T (1997) Dopamine neuron angenesis in NURR1-deficient mice. Science 276:248-249
66. Zhou CJ, Shioda S, Yada T, Inagaki N, Pleasure SJ, Kikuyama S (2002) PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr Protein Pept Sci 3:423-439